BUILDING SAFER AND MORE POTENT TREATMENTS
OUR SOLUTION
ADC Platform that targets the ideal therapeutic target, the Cell Surfaceome.
DISCOVERY
As reported by Centrose in Nature Communications, a cell’s Surfaceome is a collection of distinct interacting proteins that allow the cell to function and communicate with other cell types. Importantly, these networks are cell type specific and thus can be targeted with precision medicines.
EDCs are True Next-Gen ADCs
EDCs are constructed much like any antibody drug conjugate (ADC). Their difference lies in how EDCs work, 100% at the cells surfaceome, binding multiple extracellular proteins simultaneously and without internalization nor drug release. This is why they were named Extracellular Drug Conjugates and why they are a “True Next-Gen ADC”.
Background of Extracellular Targeting
Of all cell surface targeted cancer therapies approved today, their targets comprise a total of ~30 proteins. To expand this target list and to develop more advanced therapies, Centrose developed the EDC. The first EDC developed, uses an inhibitor to the sodium-potassium ATPase conjugated via a long and flexible linker to an antibody that binds the metastatic cancer marker called dysadherin. Both the cancer marker and ATPase form complexes on the surface of metastatic cancers. Soon after this, Centrose discovered that the ATPase interacted with multiple other surface proteins, findings later corroborated by a partnership between Centrose and the Wollscheid Group at the ETH in Zurich. Now scientists around the world are working to determine the roles and makeup of what is now coined, “The Surfaceome”.
Since these initial discoveries, Centrose has developed multiple EDCs that display high potency and selectivity of which some were reported in our cell press publication. More recently, EDCs were found to be safe when tested at efficacious levels in non-human primate models and many could not be used for making ADCs, a fact that should expand the scope of the field.
PIPELINE
EDC9 targets drug resistant NHL.
EDC1 targets metastatic cancers.
EDC8 targets certain types of lymphoma.
